Consero 2016 IP Forum for Life Sciences


Fish & Richardson is a proud sponsor of the Consero 2016 IP Forum for Life Sciences, December4-6, 2016 in San Diego, California. Principals Gwilym Attwell (Delaware), Todd Garcia (Boston), and Michael Amon (Southern California) will bemoderating three sessions during the conference and Gwilym Attwell is conference chair.

Panel details are listed below.

Sunday, December 4, 2016, 1:30 - 2:30PM PT
Integrating IP Into Your Corporate Strategy

  • How do you communicate the inner workings of your patent strategy to those in the company who lack a legal background?
  • How do you work with your management team to make sure your IP strategy complements the overall business strategy?
  • How can you more fully incorporate your IP team and outside counsel into the business?
  • What unique IP issues do clinical trials yield?
  • How have you worked effectively with the Office of the CEO as well as HR, Legal, and Communications to supervise change initiatives and supply IP-specific guidance?

Joel Harris, Senior Director, IP, InCube Labs
Melodie Henderson, Associate GC, IP, Minerva Neurosciences, Inc.
Jim MacDonald, Chief IP Officer, Juno Therapeutics
Mary Naggs, Associate GC, Apricus Biosciences, Inc.
Michael Robinson, Senior IP Counsel, Agenus, Inc.

Todd Garcia, Principal, Fish & Richardson

Sunday, December 4, 2016, 3:30 - 4:30PM PT
Knowledge Bridge: Developing A Winning IP Litigation Strategy

  • How have you been able to ensure your patent prosecution stands up to future laws and trends?
  • What is your organization’s risk profile, and how does this impact your IP litigation strategy?
  • What is your litigation strategy regarding biosimilars?
  • How have you worked with outside counsel to ensure efficiency and accountability throughout the litigation process?

Mike Amon, Principal, Fish & Richardson

Monday, December 5, 2016, 2:00 - 3:00PM PT
Knowledge Bridge: A View From The Trenches Of The Most-Active Forum For Patent Validity Challenges - The PTAB

In 2016, the PTAB appears to be ahead of the Eastern District of Texas to become the most active forum for patent validity challenges. With IPR proceedings in biopharma steadily rising over the years, what has changed in post-grant practice for the life sciences industry, and how do those changes impact your IP strategy? In this interactive session, we will address recent developments that impact the scope and frequency of institution, recent decisions involving biopharma patents, and what is likely to come in the future.

Gwilym Attwell, Principal, Fish & Richardson